KOD | Ticker Profile - Titan Protect

KOD

Kodiak Sciences Inc.

Healthcare · Biotechnology · NGM

$31.05

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.26

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-208.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$59.50

+92% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

https://kodiak.com

Country: United States Employees: 130 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.595

Excellent risk-adjusted returns

Kelly Fraction

0.1253

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

3.114

Returns exceed worst-case losses — strong risk profile

Annual Return

252.6%

Historical annualised return based on price data

Max Drawdown

-81.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.32

Significantly more volatile than the market

52W High

$47.84

35% below the year high

52W Low

$3.26

852% above the year low

Avg Volume

1,066,763

Average daily shares traded — higher means easier to buy and sell

Short Ratio

16.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

25.9%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

49.95

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.54

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.42

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-52,154,248

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-230,664,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$80.00

Target Median

$59.50

Target Low

$56.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go